Suarez-Benjumea A, Gonzalez-Corvillo C, Bernal-Blanco G, Pascasio-Acevedo JM, Gonzalez-Roncero F, Perez-Valdivia MA, Suñer-Poblet M, Gentil-Govantes MA. New Antivirals for Hepatitis C Infection Among Infected Kidney Transplant Recipients: A Case Report.
Transplant Proc 2016;
47:2672-4. [PMID:
26680070 DOI:
10.1016/j.transproceed.2015.09.047]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2015] [Accepted: 09/17/2015] [Indexed: 10/22/2022]
Abstract
The most common hepatopathy in end-stage renal disease is chronic hepatitis C virus (HCV) infection, which decreases allograft and patient survival in kidney transplants. Until last year we did not have treatments free of interferon, which was contraindicated after renal transplantation owing to the risk of allograft rejection. Recently, new drugs have been discovered for interferon-free regimens. These drugs present a cure rate of up to 90% and can be used in transplant recipients. Here we present our 1st 3 cases. In our experience, new antivirals have proven to be effective and safe for the treatment of HCV hepatopathy in kidney transplant recipients and liver-kidney transplantation, thus helping us to prevent complications related to HCV infection in transplant recipients.
Collapse